Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Top Cited Papers
- 13 April 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (14), 1460-1468
- https://doi.org/10.1001/jama.2011.406
Abstract
Research from JAMA — Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-upKeywords
This publication has 20 references indexed in Scilit:
- Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspectsJournal of Crohn's and Colitis, 2010
- Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritisAnnals Of The Rheumatic Diseases, 2010
- Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque PsoriasisArchives of Dermatology, 2010
- Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort studyArthritis Research & Therapy, 2010
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort studyAnnals Of The Rheumatic Diseases, 2009
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2008
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseGastroenterology, 2003